Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790–5.

NOTES

Bhattacharjee, ARichards, W GStaunton, JLi, CMonti, SVasa, PLadd, CBeheshti, JBueno, RGillette, MLoda, MWeber, GMark, E JLander, E SWong, WJohnson, B EGolub, T RSugarbaker, D JMeyerson, MengU01 CA084995/CA/NCI NIH HHS/U01 CA84995/CA/NCI NIH HHS/Research Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5. doi: 10.1073/pnas.191502998. Epub 2001 Nov 13.

Abstract

We have generated a molecular taxonomy of lung carcinoma, the leading cause of cancer death in the United States and worldwide. Using oligonucleotide microarrays, we analyzed mRNA expression levels corresponding to 12,600 transcript sequences in 186 lung tumor samples, including 139 adenocarcinomas resected from the lung. Hierarchical and probabilistic clustering of expression data defined distinct subclasses of lung adenocarcinoma. Among these were tumors with high relative expression of neuroendocrine genes and of type II pneumocyte genes, respectively. Retrospective analysis revealed a less favorable outcome for the adenocarcinomas with neuroendocrine gene expression. The diagnostic potential of expression profiling is emphasized by its ability to discriminate primary lung adenocarcinomas from metastases of extra-pulmonary origin. These results suggest that integration of expression profile data with clinical parameters could aid in diagnosis of lung cancer patients.
Last updated on 02/17/2021